Please check your internet connection and try again.
# Sompraz HP (Esomeprazole/Amoxicillin/Clarithromycin)
## Overview
Sompraz HP is a therapeutic "Helicobacter Pylori Kit." It is a co-packaged combination therapy containing a Proton Pump Inhibitor (Esomeprazole), a penicillin antibiotic (Amoxicillin), and a macrolide antibiotic (Clarithromycin).
## Primary Indications
Eradication of *Helicobacter pylori* infection to reduce the risk of duodenal ulcer recurrence.
## Adult Dosing
The standard regimen comprises:
* **Esomeprazole:** 20 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
* **Duration:** Typically administered for 7 to 14 days, depending on local resistance patterns and clinical guidelines.
## Pediatric Dosing
Safety and efficacy in pediatric patients for this specific triple-combination pack have not been established. Use in patients <18 years is generally not recommended without specialist consultation due to varying weight-based requirements for components.
## Dose Adjustments
* **Renal Impairment:** Amoxicillin requires adjustment in severe renal impairment (CrCl <30 mL/min). If CrCl is 10-30 mL/min, the standard dosing interval may need extension. If <10 mL/min, avoid or significantly reduce dosage.
* **Hepatic Impairment:** Use caution with Clarithromycin; accumulation may occur. Esomeprazole dose should not exceed 20 mg/day in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to Esomeprazole, Amoxicillin, Clarithromycin, or any other macrolide or beta-lactam antibiotics.
* Concomitant use with drugs dependent on CYP3A4 for metabolism where elevation causes serious toxicity (e.g., pimozide, cisapride, ergotamine).
* History of cholestatic jaundice or hepatic dysfunction associated with prior Clarithromycin use.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, dysgeusia (metallic taste), and headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe cutaneous adverse reactions (SCARs such as SJS/TEN), anaphylaxis, and prolongation of the QT interval.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clarithromycin is a potent CYP3A4 inhibitor; increased levels of statins (e.g., atorvastatin), warfarin, and midazolam may occur. Monitor INR closely if on warfarin.
* **pH-Dependent Drugs:** Esomeprazole inhibits absorption of drugs requiring acidic gastric environment (e.g., atazanavir, ketoconazole).
* **Methotrexate:** PPIs may increase methotrexate levels.
## Monitoring
* Monitor for signs of hypersensitivity/anaphylaxis.
* Assess for persistent diarrhea (potential *C. difficile*).
* Baseline and periodic ECG if the patient is at risk for QT prolongation.
* Renal function (during long-course therapy).
## Clinical Pearls
* **Adherence is Critical:** Success of *H. pylori* eradication is highly dependent on patient compliance with the full course.
* **Administration:** Esomeprazole should be taken at least 60 minutes before a meal.
* **Resistance:** Clarithromycin resistance is rising globally; consider current local susceptibility patterns when selecting a regimen.
* **Alcohol/Tobacco:** Discourage use, as these can irritate the gastric mucosa and impair ulcer healing.
***
**Educational Disclaimer:** This information is for educational purposes and does not substitute for clinical judgment. Always verify current prescribing information, local antimicrobial susceptibility patterns, and institutional guidelines prior to prescribing or administering medication.
